Health service utilisation data and rates of change of pulmonary function and weight in the year prior to and the year following commencement of lumacaftor/ivacaftor in 24 adults with cystic fibrosis
| Year prior to commencement | Year following commencement | p-value | |
| Health service utilisation data | |||
| Pulmonary exacerbations requiring hospitalisation n | 3 (2–4) | 1.5 (1–2) | 0.0002 |
| Hospitalisation (on ward) days | 27 (18–58) (range 10–103) | 17 (10–25) (range 1–70) | 0.0002 |
| IVAB usage days | 45 (21–75) (range 10–280) | 27 (11–52) (range 1–167) | 0.0007 |
| Annual rate of change in pulmonary function and weight | |||
| FEV1 L | −0.084±0.046 | 0.027±0.041 | 0.077 |
| FVC L | −0.04±0.10 | 0.00±0.06 | 0.75 |
| FEF25–75% L | −0.07±0.02 | 0.02±0.02 | 0.007 |
| FEV1 % pred | −2.10±1.18 | 1.45±1.13 | 0.035 |
| FVC % pred | −0.69±2.11 | 1.27±1.51 | 0.46 |
| FEF25–75% % pred | 0.07±0.20 | 0.07±0.05 | 0.97 |
| Weight kg | −0.62±0.89 | 2.60±0.88 | 0.013 |
Health service utilisation data are presented as median (interquartile range); pulmonary function and weight data show mean change per year (slope±se) using linear regression modelling of all clinical measurements in each year-long period. IVAB: intravenous antibiotic; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC. p-value for difference between year prior and year following commencement (Wilcoxon signed-rank test for health service utilisation data; weighted linear regression analyses for pulmonary function and weight data).